We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest close session, Vertex Pharmaceuticals (VRTX - Free Report) was down 2.38% at $436.16. This move lagged the S&P 500's daily loss of 0.11%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq gained 0.35%.
The drugmaker's shares have seen a decrease of 6.56% over the last month, not keeping up with the Medical sector's loss of 4.34% and the S&P 500's gain of 0.51%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is scheduled to release its earnings on May 4, 2026. It is anticipated that the company will report an EPS of $4.43, marking a 9.11% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.59% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $19.11 per share and revenue of $12.97 billion, indicating changes of +3.86% and +8.05%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.43% downward. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 23.38. This represents a premium compared to its industry average Forward P/E of 20.53.
Investors should also note that VRTX has a PEG ratio of 1.69 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.63 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
In the latest close session, Vertex Pharmaceuticals (VRTX - Free Report) was down 2.38% at $436.16. This move lagged the S&P 500's daily loss of 0.11%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq gained 0.35%.
The drugmaker's shares have seen a decrease of 6.56% over the last month, not keeping up with the Medical sector's loss of 4.34% and the S&P 500's gain of 0.51%.
The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is scheduled to release its earnings on May 4, 2026. It is anticipated that the company will report an EPS of $4.43, marking a 9.11% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.59% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $19.11 per share and revenue of $12.97 billion, indicating changes of +3.86% and +8.05%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.43% downward. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 23.38. This represents a premium compared to its industry average Forward P/E of 20.53.
Investors should also note that VRTX has a PEG ratio of 1.69 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.63 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 148, this industry ranks in the bottom 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.